Breast cancer patients profiled to determine drug efficacy
Researchers have identified which breast cancer patients should be treated with anthracyclines and who can safely avoid side effects of the drugs, a study shows.
Scientists from precision oncology company Agendia published a paper in JCO Precision Oncology, which demonstrates HER2-negative (HR+HER2-) early-stage breast cancer (EBC) patients are most likely to benefit from anthracycline-based chemotherapy.
The results, drawn from Agendia’s FLEX Study, showed patients with H2 tumours demonstrated significantly improved three-year invasive disease-free survival (IDFS) with either anthracycline and taxane-based chemotherapy (AC-T) versus adjuvant taxane with cyclophosphamide (TC).
The patients were profiled using MammaPrint and BluePrint, a genetic profiling test assessing risk of distant metastasis and a molecular subtyping assay respectively.
While anthracyclines are highly effective antitumour agents, they are associated with potentially serious toxicities, including cardiotoxicity and secondary leukaemias. Multiple randomised controlled trials have attempted to determine whether anthracycline-free chemotherapy regimens are non-inferior to anthracycline-containing regimens in clinically high-risk HER2-negative EBC but found no significant difference among HR+HER2- patients.
“Patients with HR+HER2-negative breast cancer who are candidates for adjuvant chemotherapy continue to face uncertainty around whether they will derive meaningful benefit from anthracycline-containing regimens,” said Joyce O’Shaughnessy, Principal Investigator for the FLEX Study.
“This long-standing clinical dilemma underscores the need for predictive biomarkers that can identify which patients are most likely to benefit from anthracyclines and who may safely avoid unnecessary toxicity.”
“This study answers a question that randomised clinical trials have been unable to resolve, illustrating the value of genomic profiling to predict benefit from a specific cancer therapy,” added William Audeh, Chief Medical Officer of Agendia and co-author of the study.
“The FLEX Study highlights the power of a multi-modal real-world evidence database to produce robust, clinically relevant data which not only inform treatment decisions, but also change clinical practice guidelines.”
